lactic acid has been researched along with Hypertrophy, Left Ventricular in 18 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Hypertrophy, Left Ventricular: Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Moxonidine is a new centrally active imidazoline-receptor agonist being effectively applied in the treatment of arterial hypertension due to its sympathicolytic potency." | 7.71 | [Effect of the imidazoline receptor agonist moxonidine on hemodynamics, coronary circulation, metabolic ischemia markers and the neurohumoral system in patients with essential hypertension. Effects of moxonidine on coronary circulation]. ( Hamel, M; Hamm, C; Miric, M; Mitrovic, V; Thormann, J, 2001) |
| "Forty-one patients operated on for isolated aortic valve stenosis were randomly assigned to continuous coronary infusion with either potassium or esmolol during cardiopulmonary bypass." | 5.10 | Efficacy of esmolol as a myocardial protective agent during continuous retrograde blood cardioplegia. ( Al Attar, N; Callebert, J; Lessana, A; Maillet, JM; Mebazaa, A; Medini, B; Nataf, P; Payen, D; Raffoul, R; Ramadan, R; Ruffenach, A; Scorsin, M; Simoneau, F, 2003) |
| "Moxonidine is a new centrally active imidazoline-receptor agonist being effectively applied in the treatment of arterial hypertension due to its sympathicolytic potency." | 3.71 | [Effect of the imidazoline receptor agonist moxonidine on hemodynamics, coronary circulation, metabolic ischemia markers and the neurohumoral system in patients with essential hypertension. Effects of moxonidine on coronary circulation]. ( Hamel, M; Hamm, C; Miric, M; Mitrovic, V; Thormann, J, 2001) |
| "As evidence on the predominant type of cardiac hypertrophy due to endurance running training is inconsistent, the aim of this study was to investigate the effect of increased training volume on echocardiographic variables of distance runners." | 2.72 | Concentric myocardial hypertrophy after one year of increased training volume in experienced distance runners. ( Raugaliene, R; Stasiulis, A; Venckunas, T, 2006) |
| "Development of heart failure is known to be associated with changes in energy substrate metabolism." | 1.39 | Pressure-overload-induced heart failure induces a selective reduction in glucose oxidation at physiological afterload. ( Basu, R; Clanachan, A; Gandhi, M; Kassiri, Z; Lopaschuk, GD; Mori, J; Oudit, GY; Zhabyeyev, P, 2013) |
| "Exercise-induced cardiac hypertrophy has been recently identified to be regulated in a sex-specific manner." | 1.37 | Sex differences in physiological cardiac hypertrophy are associated with exercise-mediated changes in energy substrate availability. ( Benz, V; Böhm, C; Dragun, D; Foryst-Ludwig, A; Gürgen, D; Kintscher, U; Kreissl, MC; Mai, K; Regitz-Zagrosek, V; Schubert, C; Sprang, C; Spranger, J; Stawowy, P; Thalke, B; Unger, T, 2011) |
| "and results Left ventricular hypertrophy was induced surgically in Sprague-Dawley rats by inter-renal aortic constriction." | 1.35 | Western diet impairs metabolic remodelling and contractile efficiency in cardiac hypertrophy. ( Akki, A; Seymour, AM, 2009) |
| "Captopril (23." | 1.29 | Captopril cardioplegia on myocardial protection in the hypertrophied rat hearts. ( Xu, SC; Zhang, YH, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Hiraki, N | 1 |
| Tanaka, TD | 1 |
| Yoshimura, M | 1 |
| Schnelle, M | 1 |
| Chong, M | 1 |
| Zoccarato, A | 1 |
| Elkenani, M | 1 |
| Sawyer, GJ | 1 |
| Hasenfuss, G | 1 |
| Ludwig, C | 1 |
| Shah, AM | 1 |
| Akki, A | 1 |
| Seymour, AM | 1 |
| Foryst-Ludwig, A | 1 |
| Kreissl, MC | 1 |
| Sprang, C | 1 |
| Thalke, B | 1 |
| Böhm, C | 1 |
| Benz, V | 1 |
| Gürgen, D | 1 |
| Dragun, D | 1 |
| Schubert, C | 1 |
| Mai, K | 1 |
| Stawowy, P | 1 |
| Spranger, J | 1 |
| Regitz-Zagrosek, V | 1 |
| Unger, T | 1 |
| Kintscher, U | 1 |
| Zhabyeyev, P | 1 |
| Gandhi, M | 1 |
| Mori, J | 1 |
| Basu, R | 1 |
| Kassiri, Z | 1 |
| Clanachan, A | 1 |
| Lopaschuk, GD | 2 |
| Oudit, GY | 1 |
| Scorsin, M | 1 |
| Mebazaa, A | 1 |
| Al Attar, N | 1 |
| Medini, B | 1 |
| Callebert, J | 1 |
| Raffoul, R | 1 |
| Ramadan, R | 1 |
| Maillet, JM | 1 |
| Ruffenach, A | 1 |
| Simoneau, F | 1 |
| Nataf, P | 1 |
| Payen, D | 1 |
| Lessana, A | 1 |
| Minakawa, M | 1 |
| Takeuchi, K | 2 |
| Ito, K | 1 |
| Tsushima, T | 1 |
| Fukui, K | 1 |
| Takaya, S | 1 |
| Fukuda, I | 1 |
| Venckunas, T | 1 |
| Stasiulis, A | 1 |
| Raugaliene, R | 1 |
| Podesser, BK | 1 |
| Jain, M | 1 |
| Ngoy, S | 1 |
| Apstein, CS | 1 |
| Eberli, FR | 1 |
| Barillas, R | 1 |
| Friehs, I | 1 |
| Cao-Danh, H | 2 |
| Martinez, JF | 1 |
| del Nido, PJ | 2 |
| Buenaventura, P | 1 |
| Glynn, P | 1 |
| Simplaceanu, E | 1 |
| McGowan, FX | 1 |
| Zhang, YH | 1 |
| Xu, SC | 1 |
| Raizada, V | 1 |
| Pathak, D | 1 |
| Avery, G | 1 |
| Woodfin, B | 1 |
| Ishibashi, Y | 1 |
| Shimada, T | 1 |
| Nosaka, S | 1 |
| Sano, K | 1 |
| Oyake, N | 1 |
| Kobayashi, S | 1 |
| Umeno, T | 1 |
| Yoshitomi, H | 1 |
| Morioka, S | 1 |
| Yuan, F | 1 |
| Brandt, NR | 1 |
| Pinto, JM | 1 |
| Wasserlauf, BJ | 1 |
| Myerburg, RJ | 1 |
| Bassett, AL | 1 |
| Mitrovic, V | 1 |
| Hamel, M | 1 |
| Miric, M | 1 |
| Thormann, J | 1 |
| Hamm, C | 1 |
| Mohri, M | 1 |
| Ichiki, T | 1 |
| Hirooka, Y | 1 |
| Takeshita, A | 1 |
| Leong, HS | 1 |
| Grist, M | 1 |
| Parsons, H | 1 |
| Wambolt, RB | 1 |
| Brownsey, R | 1 |
| Allard, MF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Outcome of Esmolol Potassium Cardioplegia Compared to Potassium Cardioplegia in Patients With Solitary Valvular Disease; Randomized Controlled Study[NCT04306913] | 80 participants (Anticipated) | Interventional | 2020-04-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for lactic acid and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Efficacy of esmolol as a myocardial protective agent during continuous retrograde blood cardioplegia.
Topics: Adrenergic beta-Antagonists; Aged; Aortic Valve Stenosis; Cardioplegic Solutions; Cardiopulmonary By | 2003 |
Concentric myocardial hypertrophy after one year of increased training volume in experienced distance runners.
Topics: Adolescent; Adult; Cardiomegaly; Exercise Test; Humans; Hypertrophy, Left Ventricular; Lactic Acid; | 2006 |
16 other studies available for lactic acid and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
A Man With Left Ventricular Hypertrophy.
Topics: Adult; Atrophy; Cardiomyopathies; Cerebellar Diseases; Cognitive Dysfunction; Echocardiography; Gluc | 2022 |
In vivo [U-
Topics: Animals; Blood Glucose; Carbon Isotopes; Citric Acid Cycle; Disease Models, Animal; Energy Metabolis | 2020 |
Western diet impairs metabolic remodelling and contractile efficiency in cardiac hypertrophy.
Topics: Acyl-CoA Dehydrogenase; Animals; CD36 Antigens; Diabetes Mellitus, Type 2; Dietary Fats; Disease Mod | 2009 |
Sex differences in physiological cardiac hypertrophy are associated with exercise-mediated changes in energy substrate availability.
Topics: Adipose Tissue; Animals; Blotting, Western; Calorimetry; Cardiomegaly; Echocardiography; Energy Meta | 2011 |
Pressure-overload-induced heart failure induces a selective reduction in glucose oxidation at physiological afterload.
Topics: Acetyl Coenzyme A; Animals; Echocardiography; Glucose; Glucose Transporter Type 4; Heart Failure; Hy | 2013 |
Restoration of sarcoplasmic reticulum protein level by thyroid hormone contributes to partial improvement of myocardial function, but not to glucose metabolism in an early failing heart.
Topics: Animals; Calcium-Transporting ATPases; Cells, Cultured; Disease Models, Animal; Disease Progression; | 2003 |
Unveiling gender differences in demand ischemia: a study in a rat model of genetic hypertension.
Topics: Animals; Coronary Circulation; Diastole; Disease Models, Animal; Disease Susceptibility; Female; Hyp | 2007 |
Inhibition of glycogen synthase kinase-3beta improves tolerance to ischemia in hypertrophied hearts.
Topics: Animals; Body Weight; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Glycolysis; Hyper | 2007 |
Improved protection of the hypertrophied left ventricle by histidine-containing cardioplegia.
Topics: Animals; Cardiomegaly; Energy Metabolism; Heart; Heart Arrest, Induced; Histidine; Hydrogen-Ion Conc | 1995 |
Captopril cardioplegia on myocardial protection in the hypertrophied rat hearts.
Topics: Animals; Captopril; Coronary Circulation; Creatine Kinase; Heart Arrest, Induced; Hypertrophy, Left | 1994 |
Accelerated glycolysis in early hypertensive left ventricular hypertrophy.
Topics: Animals; Blood Pressure; Energy Metabolism; Glycogen; Glycolysis; Hypertrophy, Left Ventricular; Lac | 1993 |
Effects of heart rate on coronary circulation and external mechanical efficiency in elderly hypertensive patients with left ventricular hypertrophy.
Topics: Aged; Analysis of Variance; Coronary Circulation; Heart Failure; Heart Rate; Hemodynamics; Humans; H | 1996 |
Hypertrophy decreases cardiac KATP channel responsiveness to exogenous and locally generated (glycolytic) ATP.
Topics: Adenosine Triphosphate; Animals; Cats; Cell Membrane Permeability; Female; Glycolysis; Hypertrophy, | 1997 |
[Effect of the imidazoline receptor agonist moxonidine on hemodynamics, coronary circulation, metabolic ischemia markers and the neurohumoral system in patients with essential hypertension. Effects of moxonidine on coronary circulation].
Topics: Aged; Angina Pectoris; Antihypertensive Agents; Blood Flow Velocity; Coronary Circulation; Electroca | 2001 |
Endogenous nitric oxide prevents myocardial ischemia in patients with hypertension and left ventricular hypertrophy.
Topics: Aged; Cardiac Catheterization; Coronary Circulation; Enzyme Inhibitors; Female; Humans; Hypertension | 2002 |
Accelerated rates of glycolysis in the hypertrophied heart: are they a methodological artifact?
Topics: Animals; Artifacts; Blood Pressure; Glucose; Glucosephosphate Dehydrogenase; Glycolysis; Heart Rate; | 2002 |